At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Comparison of Bupropion SR and Placebo for Smoking Cessation
In Brief
A Phase 4 clinical trial evaluating Bupropion SR and Placebo Oral Tablet for Tobacco Use Disorder. Completed, enrolled 52 participants across 1 site.
Detailed Summary
The purpose of this study is to examine whether the adjunctive use of bupropion SR in the context of a psychoeducational program modified for people with schizophrenia might improve the likelihood of successful abstinence in this population. If bupropion SR is effective for reducing cigarette smoking, then it will be important to determine if decreased nicotine intake is associated with a worsening of psychotic, anxiety or depressive symptoms. In addition, it would be important to determine the effect that a reduction in nicotine stimulation would have on patient's cognitive functioning, as nicotinic receptors have been shown to regulate attention and memory function, and it is hypothesized that these functions are normalized by acute nicotine administration in people with schizophrenia
Study Details
Timeline
Interventions
150mg twice a day (starting with 150mg once a day for three days)
Comparable placebo